CompletedNot Applicable

Adolescent Transition West Africa

Burkina Faso, Mali, Niger4,300 participantsStarted 2021-12-01

Plain-language summary

This trial will serve as an outcome evaluation of 'Adolescent Transition in West Africa' (ATWA), a school-based program in Mali, Burkina Faso, and Niger for adolescents ages 10-19. The overall objectives of the project are as follows: Impact: Improved sexual and reproductive health and rights of 472,180 adolescents. Outcome 1: Improved sexual and reproductive health and rights and gender equality knowledge, intent, and behaviors among 472,180 adolescents. Outcome 2: 500 health facilities offer quality adolescent responsive SRH services that are used by adolescent girls and boys. To evaluate program impact, an external evaluation will be conducted. A pre/post cross-sectional evaluation design will be used across two evaluation years.

Who can participate

Age range

10 Years – 19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Enrolled in primary or secondary school * Participating in community group (Niger only) * Aged 10 to 19 Exclusion Criteria: * Not enrolled in school (Mali and Burkina Faso) * Younger than age 10 * Older than age 19

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Impact Indicator 1. Decrease in adolescent birth rate

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Impact 2. Decrease in proportion of adolescents who have ever been pregnant or caused a pregnancy

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Impact 3. Increase in need for family planning satisfied with modern contraception

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Impact 4. Increase in adolescent modern contraceptive prevalence rate

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Impact 5. Decrease in proportion of adolescents married

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Outcome 1.1.

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Trial details

NCT IDNCT05396664

SponsorUniversity of California, San Diego

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-06-01

View on ClinicalTrials.gov More Adolescent Development trials

Plain-language summary

Who can participate

Age range

10 Years – 19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Impact Indicator 1. Decrease in adolescent birth rate

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Impact 2. Decrease in proportion of adolescents who have ever been pregnant or caused a pregnancy

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Impact 3. Increase in need for family planning satisfied with modern contraception

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Impact 4. Increase in adolescent modern contraceptive prevalence rate

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Impact 5. Decrease in proportion of adolescents married

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023

Outcome 1.1.

Timeframe: Year 1 Evaluation: September 2021 - May 2022; Year 2 Evaluation: September 2022 - May 2023